Severe Eosinophilic Asthma: Key Decisions That Drive Effective Strategies with Targeted Therapies

Gain expert guidance on current best practice for the treatment of severe asthma, including an Interactive Decision Support Tool and expert commentaries.
Michael E. Wechsler, MD, MMSc
Program Director
Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP
Nicola Alexander Hanania, MD, MS
Linda Rogers, MD
Eileen Wang, MD, MPH
Michael E. Wechsler, MD, MMSc

Interactive Decision Support Tool

Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts.

Michael E. Wechsler, MD, MMSc
Program Director
Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP Nicola Alexander Hanania, MD, MS Linda Rogers, MD Eileen Wang, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 5, 2020 Expired: August 4, 2021

ClinicalThought

Why determining endotype is crucial to managing severe asthma.

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme and Regeneron Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue